スルファメトキサゾール/トリメトプリム配合剤の投与による血清クレアチニンの上昇とその要因：正常な腎機能を有する日本人患者を対象とした遡及的解析
書誌事項
- タイトル別名
-
- Factors Contributing to Increases in Serum Creatinine Following Treatment with a Sulfamethoxazole-trimethoprim Combination Product: Retrospective Analysis of Japanese Patients with Normal Renal Function
- スルファメトキサゾール/トリメトプリム ハイゴウザイ ノ トウヨ ニ ヨル ケッセイ クレアチニン ノ ジョウショウ ト ソノ ヨウイン : セイジョウ ナ ジンキノウ オ ユウスル ニホンジン カンジャ オ タイショウ ト シタ ソキュウテキ カイセキ
この論文をさがす
抄録
Japanese patients with normal renal function were retrospectively analyzed to characterize increases in serum creatinine (SCr) observed following the use of a sulfamethoxazole-trimethoprim (SMX-TMP) combination product and identify factors affecting these increases. In the patients studied (n=49), an individual comparison was conducted for the three factors of age group [≤74 years (n=21) vs. ≥75 years (n=28)], sex [male (n=24) vs. female (n=25)], and total dose throughout the treatment period [≤7 g (n=24) vs. ≥8 g (n=25)] to determine the extent of SCr increase following SMX-TMP combination product use. SCr increased significantly following SMX-TMP combination product use in patients ≤74 years of age and ≥75 years of age, in both males and females, and in patients with a total dose of ≥8 g (8 to 96 g) (p<0.05). Multivariate logistic regression analysis was used to determine the independence of these factors. Total dose was identified as an independent factor and had an odds ratio of 6.571 [95% confidence interval=1.735-24.882, p=0.006]. Post-treatment percent increases in SCr were compared using pre-treatment levels as the baseline. The group with a total dose of ≥8 g (mean 29.8 g) had a significant SCr increase of 18.4% (p=0.002), while the increase in the ≤7 g (mean 5.3 g) group was only 4.5%. The data showed that SCr increased by about 20% when the total dose taken over the treatment period was around 30 g (about 2.4 g as TMP) and indicated that total dose contributes more than age and sex to the post-treatment increase in SCr.<br>
収録刊行物
-
- 薬学雑誌
-
薬学雑誌 133 (5), 587-595, 2013-05-01
公益社団法人 日本薬学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390001206129110144
-
- NII論文ID
- 130003361939
-
- NII書誌ID
- AN00284903
-
- COI
- 1:STN:280:DC%2BC3snhsVKnsQ%3D%3D
-
- ISSN
- 13475231
- 00316903
-
- NDL書誌ID
- 024650890
-
- PubMed
- 23649399
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可